((Sara M. Tinsley, Ph.D., ARNP, AOCN))
The need for red blood cell transfusions takes into consideration a number of patient specific factors.
We monitor the patient's underlying condition to determine the appropriate threshold at which to start red blood cell transfusions.
Some patients may have higher thresholds for initiating transfusions, for example, if they have significant cardio or pulmonary disease.
At our institution, we generally say the lower limit for hemoglobin is 7 g/dL to require a standing order for transfusion, but this will vary by each institution and their specific protocol.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION